Nordic Life Science 1
TOP STORIES B U S IN E S S DE A L BIOTAGE ACQUIRE
S ASTREA BIOSEPARATIONS The enterprise value for Astrea is approximately 190 million USD, subject to any closing adjustments and potential milestone-based payments. G AMMA BIOSCIENCES IS a life sciences platform formed by Kohlberg Kravis Roberts & Co (KKR) to address the advanced therapy market with bioprocessing solutions. Astrea Bioseparations supplies chromatography resins, adsorbents, and columns as well as nanofiber-based purification technologies for biomanufacturing. Astrea is a global company with facilities in Europe, US, and Canada. “The acquisition is an excellent strategic fit for Biotage, and it will add to us a high-growth company with a talented global team with decades of experience. It also scales our Biologics and Advanced Therapeutics business significantly, keeping us well-positioned for the future,” says Tomas Blomquist, CEO, Biotage. Tomas Blomquist, CEO, Biotage